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1. Introduction  
Ovarian cancer is one of the most lethal among the gynaecological malignancies, affecting 1-
2% of women in developed countries (Cannistra, 2004). The lethality of ovarian cancer is 
primarily attributable to our current inability to detect the disease at an early stage, when it 
is still limited to the ovary. Therefore, the majority of patients are diagnosed when they have 
advanced-stage disease. Despite progresses in cytotoxic therapies, only 30% of patients with 
advanced-stage ovarian cancer survive 5 years after diagnosis. The insidious nature of 
ovarian cancer stems from its unique biological behaviour: ovarian carcinoma can spread by 
direct extension to adjacent organs, and exfoliated tumour cells can be transported in 
peritoneal fluid (Naora et al., 2005). Subsequent implants are characterised by their adhesion 
to mesothelial cells, migration throughout and invasion of the tumor cells into the omentum 
and peritoneum. This seeding of the peritoneal cavity is frequently associated with ascites 
formation. Only secondarily and rather late during the disease progression, are pelvic and 
para-aortic lymph nodes involved. However, the local peritoneal disease cannot be 
controlled and remains a factor leading to death (Feki et al., 2009). The cellular processes 
that lead to local and distant dissemination of ovarian cancer are not fully understood, and 
the mechanisms of interaction between cancer cells and mesothelium need to be further 
elucidated to achieve novel information on the biology of this highly aggressive form of 
cancer and possibly, to identify new potential targets for selective therapeutic strategies.  
The combined effort of clinicians and researchers has led to the identification of a number of 
molecules that might facilitate screening, diagnosis, prognosis and monitoring response to 
treatment or relapse during follow-up. These new molecules might provide specific targets 
for anti-tumour therapy with antibody-directed treatments, gene therapy or specific 
inhibitory molecules. An unexpectedly high number of these newly identified molecules 
have turned out to be cell surface-expressed ectoenzymes. Ectoenzymes are a large, 
heterogeneous class of membrane proteins whose catalytically active sites face the 
extracellular environment. The products of their catalytic activities can influence the 
extracellular environment (for example, several of these products can function as second 
messengers or regulate the recruitment of cells). Moreover, many ectoenzymes can function 
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both as receptors and signalling molecules through mechanisms that are independent from 
their catalytic activity. The nomenclature of ectoenzymes is confusing: in addition to several 
original descriptive names, many of them also have a cluster designation (CD) given by 
immunologists and an EC number assigned by biochemists.  
This chapter presents an overview of the ectoenzymes involved in ovarian cancer biology, 
development or progression (focusing on CD10, CD13, CD26, CD73, CD157, and 
Autotaxin/CD203c) and highlights the potential role of these molecules as markers for 
ovarian cancer outcome or as novel therapeutic targets. 
 
 
 
Fig. 1. Schematic representation of ectoenzymes involved in ovarian cancer progression. 
2. CD10 
2.1 Structure and expression  
Human CD10 (also known as CALLA, NEP, Neprilysin, EC 3.4.24.11) is a 100 kDa cell 
surface aminopeptidase originally characterised as a T cell differentiation antigen (Common 
Acute Lymphoblastic Leukaemia Antigen, CALLA) identified for its expression in most 
acute lymphoblastic leukaemias (Shipp et al., 1989). Subsequently, its identity with neutral 
endopeptidase 24.11 (NEP) and KII-NA was unequivocally established and a wider 
distribution attributed to the protein (Shipp et al., 1993). 
The CALLA/NEP gene spans more than 80 kilobases (kb) on chromosome 3q21-q27 and is 
composed of 24 exons (D'Adamio et al., 1989). CD10 is a 749-amino acid type II integral 
membrane glycoprotein with a single 24-amino acid hydrophobic segment that can function 
both as a transmembrane region and a signal peptide. The COOH-terminal is composed of 
700-amino acids and forms the extracellular protein fragment, whereas the 25 amino-
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terminal amino acids form the cytoplasmic tail (Ritz et al., 1980). CD10 is expressed by 
human lymphoblastic leukaemia cells, by early lymphoid progenitors (Greaves et al., 1983; 
Hoffmann-Fezer et al., 1982) and by other lymphoid malignancies (Greaves, et al., 1983). It is 
also expressed in terminally differentiated granulocytes and in non-lymphoid cells, 
including cultured fibroblasts and bone marrow stromal cells, implying that its biological 
function is not restricted to lymphoid development (Pesando et al., 1983). CD10 expression 
has been reported on epithelial cells of various tissues, such as bronchial epithelial cells, 
renal proximal tubular epithelial cells, small intestinal epithelium, biliary canaliculae (Loke 
et al., 1990), breast myoepithelium (O'Hare et al., 1991), prostate, endometrium (Suzuki et 
al., 2001) and placenta (Ino et al., 2000). Several reports have shown that CD10 is also 
expressed in selected solid tumours of the colon (Fujimoto et al., 2005), lung (Cohen et al., 
1996), breast (Burns et al., 1999), prostate (Dai et al., 2001) and ovary (Khin et al., 2003). 
2.2 Functions  
CD10 is a cell membrane-associated zinc metalloproteinase that cleaves peptide bonds on 
the amino-terminal side of hydrophobic amino acids and inactivates a variety of peptides, 
cytokines and hormones (Shipp et al., 1988). CD10 plays an important role in the 
maintenance of homeostasis in normal tissues by degrading  endothelin-1 (ET-1), 
enkephalin, oxytocin, neurotensin, bradykinin, bombesin-like peptides, and angiotensin I 
and II, among others (Erdos et al., 1989). In specific contexts, CD10 works in concert with 
CD13, BP-1 and CD26 to digest common substrates (Bowes et al., 1987). This enzyme 
network controls the local concentrations of these substrates, thus regulating their biological 
activities and the downstream signal transduction pathways (Shipp & Look, 1993).  
CD10 has been implicated in a variety of processes including stromal cell-dependent B 
lymphopoiesis (Salles et al., 1992), chemotactic and inflammatory responses (Madara et al., 
1993), and T cell activation (Massaia et al., 1988). Apart from the hematopoietic 
compartment, CD10 participates in the final stage of peptide hydrolysis in the renal 
proximal tubules and the small intestine. 
Several reports showed that CD10 plays a role in neoplastic transformation and tumour 
progression in selected human malignancies by inactivating ET-1 or bombesin, both 
involved in autocrine/paracrine stimulation of tumour cell proliferation and migration in 
many epithelial cancers, including breast (Burns, et al., 1999), lung (Cohen, et al., 1996) and 
prostate cancers (Dai, et al., 2001).  
CD10 is expressed in the stroma of malignant ovarian carcinomas, but not in benign 
adenomas or in normal ovaries, and its expression inversely correlates with histologic 
tumour grade (Khin, et al., 2003). In ovarian carcinoma, ET-1 promotes cell growth, invasion 
and angiogenesis by acting as an autocrine/paracrine growth factor (Bagnato et al., 1999; 
Salani et al., 2000). CD10 may directly influence the local concentration of ET-1 via its 
enzymatic activity thus contrasting the mitogenic effects of ET-1, suggesting that CD10 plays 
a role in the biology of neoplastic transformation or in the control of ovarian cancer 
progression (Kajiyama et al., 2005). It has been suggested that CD10 may function as a 
tumour suppressor factor in ovarian cancer progression, as well as in lung and prostate 
cancer  (Papandreou et al., 1998). 
In addition to its role in the control of ovarian carcinoma progression, Kajiyama et al. 
(Kajiyama, et al., 2005) demonstrated that CD10 enhances susceptibility to paclitaxel in the 
SKOV3 ovarian carcinoma cell line, resulting in increased apoptosis and reduced tumour 
formation and invasiveness in in vivo models. This evidence suggests that CD10 might serve as 
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a potential target for gene therapy in metastatic ovarian carcinoma. However, no experimental 
data in this regard is so far available, and this aspect deserves further investigation. 
3. CD13 
3.1 Structure and expression  
Human CD13 was isolated in 1963 from pig kidney (Pfleiderer et al., 1963) and is a 
transmembrane protein also known as aminopeptidase N (APN), alanine aminopeptidase, 
microsomal aminopeptidase, amino oligopeptidase, GP150. CD13 cleaves N-terminal 
neutral amino acids of a number of peptides and proteins. The CD13 gene is located on the 
long arm of chromosome 15 and the coding sequence spans 20 exons (Lerche et al., 1996). 
CD13 consists of 967 amino acids constituting a short N-terminal cytoplasmic domain, a 
single transmembrane fragment and a large ectodomain encompassing the active site (Olsen 
et al., 1988).  
The CD13 protein is predominantly expressed in stem cells and cells of the granulocytic and 
monocytic lineages at discrete stages of differentiation (Razak et al., 1992). Non-
hematopoietic cells, such as renal proximal tubular epithelial cells, small intestinal 
epithelium, biliary canaliculae, bone marrow stromal cells, fibroblasts and osteoclasts are 
also CD13-positive (Metzgar et al., 1981; Noren, 1986). Deregulated expression of membrane 
and/or soluble forms of CD13 has been observed in many diseases.  For example, CD13 is 
overexpressed in acute and chronic myeloid leukaemias (Antczak et al., 2001) and in 
anaplastic large cell lymphomas (Dunphy et al., 2000). High expression of CD13 has been 
detected in various solid tumours such as melanoma (Fujii et al., 1995), renal (Kitamura et 
al., 1990), pancreas (Ikeda et al., 2003), colon (Hashida et al., 2002), prostate (Ishii et al., 
2001a), gastric (Carl-McGrath et al., 2004), thyroid (Kehlen et al., 2003) and ovarian cancers 
(Yamashita et al., 2007). In ovarian cancer CD13 expression is associated with the 
histological subtype: over 80% of serous and mucinous carcinomas but only 20% of clear cell 
carcinomas are CD13-positive (van Hensbergen et al., 2004). Moreover, CD13 also exists as a 
soluble form, likely originating from shedding of the membrane protein, which has a potent 
enzymatic activity in the plasma and reactive effusions of cancer patients, such as ascites 
from ovarian cancer patients  (van Hensbergen et al., 2002).   
3.2 Functions  
CD13 is a multifunctional protein acting as an enzyme, a receptor and a signalling molecule. 
As an enzyme, CD13 regulates the activity of numerous peptides involved in important 
biological processes by removing their N-terminal aminoacids, mainly neutral aminoacids 
(Noren, 1986). CD13 hydrolyses the N-terminal Arg of angiotensin III to generate 
angiotensin IV (Danziger, 2008) and participates in the metabolism of glutathione, 
somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin FQ and peptides 
derived from the thrombin receptor (Noble et al., 1997). In the intestinal brush border, the 
CD13 enzymatic domain faces the lumen and has been supposed to play an important role 
in the final stages of the digestion of small peptides (Semenza, 1986). CD13 has been 
postulated to cooperate with CD10 in the hydrolysis of oligopeptides in the small intestine 
(Semenza, 1986), and to inactivate opioid peptides and enkephalins in the brain (Matsas et 
al., 1985) and the chemotactic peptide Met-Leu-Phe during neutrophil-mediated 
inflammatory responses (Connelly et al., 1985). 
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CD13 also acts as a receptor for coronaviruses, which exploit the endocytosis of the molecule 
to enter into respiratory and intestinal epithelial cells (Nomura et al., 2004). Moreover, CD13 
is involved in transduction of intracellular signals, converging on mitogen-activated protein 
kinases, such as ERK1/2, JNK, and p38, in association with auxiliary proteins such as 
galectin-3 (Santos et al., 2000), galectin-4 (Danielsen et al., 1997), RECK (Miki et al., 2007) and 
the tumour-associated antigen L6 (Chang et al., 2005). 
CD13 activates or inactivates bioactive peptides on the cell surface, thus regulating their 
activities on adjacent cells. CD13 has a wide range of functions, including a role in antigen 
presentation by processing antigenic peptides protruding from MHC class II molecules 
(Larsen et al., 1996), in phagocytosis (Mina-Osorio et al., 2005), in lymphocyte and monocyte 
adhesion and aggregation (Mina-Osorio et al., 2006) and intracellular signal transduction 
(Santos, et al., 2000), in stem cell differentiation (Chen et al., 2007), cholesterol uptake 
(Knopfel et al., 2007) and spermatozoid motility (Carlsson et al., 2006).  
Several studies have confirmed a correlation between CD13 expression and increased 
malignant behaviour in melanoma (Carlsson, et al., 2006), prostate (Ishii, et al., 2001a), colon 
(Hashida, et al., 2002) and lung cancers (Chang, et al., 2005). In these tumours it is 
implicated in cell motility and in the degradation of and invasion through the extracellular 
matrix (ECM) (Saiki et al., 1993). By contrast, an inverse correlation has been reported 
between CD13 expression and tumour progression in renal cancer (Ishii et al., 2001b). 
Several studies have demonstrated that CD13 expression is induced in tumour 
microvascular endothelial cell by angiogenic cytokines and hypoxia and that it regulates 
endothelial cell tube formation both in in vitro (Hashida, et al., 2002) and in in vivo models 
(Bhagwat et al., 2001).  
Functional studies indicate that CD13 expression is associated with a long spindle fibroblast-
like morphology and a migratory phenotype accompanied by enhanced secretion of MMP-2 
in various ovarian cancer cell lines (Terauchi et al., 2007). Since CD13 is involved in cell 
motility, in the invasive potential of tumour cells and in the neoangiogenic processes, it 
holds promise as a therapeutic tumour target. In ovarian cancer it has been demonstrated 
that suppression of CD13 activity by specific inhibitors (including blocking antibodies, 
bestatin or actinonin) reduces the proliferative, migratory and angiogenic potential of 
tumour cells, as well as the peritoneal dissemination in vivo in mouse models, leading to 
prolonged survival (Terauchi, et al., 2007). It has also been determined that CD13 is involved 
in the chemosensivity and radiosensitivity of ovarian cancer cells. Indeed, combined 
treatment of tumour cells with bestatin and paclitaxel showed a significant increase in 
apoptosis and an improved outcome of ovarian cancer patients (Yamashita, et al., 2007). 
Taken together, the results from these studies suggest that inhibition of CD13 enzymatic 
activity may provide a new approach for improving the efficacy of ovarian carcinoma 
therapy, leading to reduced cell proliferation, motility, invasiveness, angiogenesis and 
chemoresistance of ovarian cancer cells. 
4. CD26 
4.1 Structure and expression 
CD26, also known as dipeptidyl peptidase IV (DPPIV), adenosine deaminase binding 
protein (ADAbp) or EC 3.4.14.5, is a multifunctional type II cell surface glycoprotein. CD26 
is a 110 kDa aminopeptidase that is catalytically active only as a dimer. Each monomer 
consists of two domains, an ǂ/ǃ-hydrolase domain (residues 39–51 and 501–766) and an 
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eight-blade ǃ-propeller domain (residues 59–497), that enclose a large cavity of ~ 30–45A° in 
diameter. Access to this cavity is provided by a large side opening of ~15A°(Aertgeerts et al., 
2004). However, only elongated peptides, or unfolded or partly unfolded protein fragments, 
can reach the small pocket within this cavity that contains the active site. The main 
enzymatic activity of CD26 is a serine protease activity with a post-proline dipeptidyl 
aminopeptidase activity, preferentially cleaving Xaa-Pro or Xaa-Ala dipeptides (where Xaa 
is any amino acid except Pro) from the N-terminus of polypeptides. 
CD26 contains nine potential N-linked glycosylation sites that lie predominantly on the 
propeller domain, near the dimerization interface (Engel et al., 2003). The human CD26 gene 
consists of 26 exons and is located on the long arm of chromosome 2 (Tanaka et al., 1992).  
4.2 Functions 
CD26 exerts pivotal roles in nutrition, metabolism, immune and endocrine systems, bone 
marrow mobilization, cancer growth and cell adhesion. CD26 activates or deactivates 
various bioactive peptides on the cell surface or in the extracellular environment, by 
cleaving them enzymatically, therefore regulating their availability for adjacent cells. CD26 
substrates include cytokines and several chemokines: substance P, chorionic gonadotropin, 
tumour necrosis factor ǂ (TNF-ǂ), interleukin-2, stromal cell-derived factor 1a, RANTES, 
neuropeptide Y, peptide YY, glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent 
insulinotropic peptide  (Gorrell, 2005). Besides its enzymatic activity, CD26 shows a variety 
of functions, including regulation of inflammatory and immunological responses, signal 
transduction, interactions with extracellular matrix proteins and apoptosis.  
CD26 ligands include adenosine deaminase (ADA) (Morrison et al., 1993), kidney Na+/H+ 
ion exchanger 3 (Girardi et al., 2001) and fibronectin (Cheng et al., 2003). 
CD26 has been consistently associated with cancer since its identification (ten Kate et al., 
1984). A number of recent studies have provided evidence that CD26 plays a role in discrete 
steps of tumour progression, such as cell adhesion, invasion and cell cycle arrest 
(Pethiyagoda et al., 2000). In selected carcinoma tissues, CD26 is misexpressed and it can 
function either as an oncogene or as a tumour suppressor gene. Its expression is upregulated 
and associated with tumour aggressiveness in T and B lymphomas and leukaemias (Bauvois 
et al., 1999; Carbone et al., 1995; Dang et al., 2003), thyroid follicular tumours (de Micco et 
al., 2008), papillary carcinomas, astrocytic tumours (Stremenova et al., 2007) and 
gastrointestinal stromal tumours (Yamaguchi et al., 2008). Conversely, loss of CD26 occurs 
during malignant transformation of melanocytes into melanoma (Wesley et al., 1999), 
indicating a possible role of the molecule in suppressing the malignant transformation of 
melanocytes. 
The precise biological mechanism through which CD26 regulates tumour cell progression 
remains controversial. According to Wesley et al.,  high CD26 expression leads to a loss of 
tumorigenicity through its serine protease activity (Wesley, et al., 1999).  On the other hand, 
the suppressive effect of CD26 on melanoma’s malignant phenotype is related neither to the 
protease activity located at the extracellular domain nor to the signal transduction related to 
the cytoplasmic domain (Pethiyagoda et al., 2000). 
In 2002 Kajiyama et al. first described the expression of CD26 in ovarian carcinoma cell lines 
and tissues. CD26 immunoreactivity was observed on surgically resected ovarian carcinoma 
of different histotypes, but was not found in stromal cells. CD26 expression in ovarian 
cancer cell lines is associated with an epithelioid morphology. Indeed, forced expression of 
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CD26 in an ovarian cancer cell line results in marked morphological changes from a 
fibroblastic/spindle-shaped appearance toward an epithelioid pattern, which is paralleled 
by the shift from mesenchymal to epithelial markers (Kajiyama et al., 2002). 
Exogenous expression of CD26 leads to a significant reduction in the invasive potential in 
ovarian carcinoma cell lines in vitro and an increased E-cadherin expression. Indeed, CD26 
expression in ovarian cancer cell lines positively correlates with E-cadherin expression and 
induces the upregulation of both E-cadherin and ǃ-catenin, which play a key role in the 
suppression of invasive and metastatic phenotype of cancer cells (Kajiyama et al., 2003). 
Moreover, in ovarian carcinoma cell lines CD26 expression negatively correlates with MMP-
2 expression, and the expression levels of both MMP-2 and MT1-MMP are significantly 
reduced in CD26-transfected cells. Overexpression of CD26 also increases expression levels 
of TIMP-1 and TIMP-2, known to be key inhibitors of tumour invasion, angiogenesis and 
metastasis (Kikkawa et al., 2005). 
Overexpression of CD26 reduced intraperitoneal dissemination of carcinoma cells and 
prolonged survival time in vivo in a mouse orthotopic model. Ovarian carcinoma cell lines 
with higher CD26 expression has significantly less metastatic potential when injected into 
the abdominal cavity of nude mice than the CD26-negative control cells (Mizutani et al., 
2003). Consistent with this, the intensity of CD26 immunohistochemical staining in tissues 
proved to be stronger in well-differentiated and non-infiltrating ovarian carcinomas, thus 
indicating that the decrease of CD26 is related to neoplastic transformation and tumour 
progression (Zhang et al., 2008). 
A positive correlation between CD26 expression and sensitivity to paclitaxel has been 
described in several ovarian carcinoma cell lines. Forced expression of CD26 in a CD26-
negative ovarian cancer cell line significantly enhanced sensitivity to paclitaxel by increasing 
the rate of apoptotic cells through the repression of the transcriptional factor Twist, a master 
regulator of epithelial-mesenchymal transition, linked to paclitaxel resistance. These data 
were corroborated by the observation that paclitaxel-resistant NOS-PR cells showed 
reduced expression of CD26. However, no significant alteration in paclitaxel sensitivity was 
observed in the presence of a specific inhibitor of DPPIV activity in CD26-transfected or 
natively CD26-overexpressing cells (Kajiyama et al., 2010).  
Further understanding of the anti-invasive effect of CD26 may prove useful in devising new 
strategies in the control of ovarian cancer and other carcinomas. Like other membrane-
bound peptidases, CD26 may soon be destined for use not only as a new 
diagnostic/prognostic marker, but also as a molecular target in novel therapeutic strategies. 
5. CD73 
5.1 Structure and expression 
CD73, also known as ecto-5′-nucleotidase (ecto-5′-NT), is a glycosylphosphatidylinositol 
(GPI)-anchored ectoenzyme composed of two identical subunits of 70-74 kDa. The mature 
protein consists of 548 amino acids and corresponds to a molecular mass of ~63 kDa (Airas 
et al., 1993). The human CD73 gene has been mapped to region q14-q21 of chromosome 6. 
CD73 is abundantly expressed by vascular endothelial cells (Jalkanen et al., 2008) and by a 
subpopulation of peripheral blood lymphocytes represented by regulatory T cells and 
primed uncommitted CD4-positive T cells. Follicular dendritic cells (Airas, 1998), intestinal 
epithelial cells (Strohmeier et al., 1997), fibroblasts (Nemoto et al., 2004), cardiomyocytes 
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(Carneiro-Ramos et al., 2004), neurons, oligodendrocytes (Maienschein et al., 1996) and  
mesenchymal stem cells (Barry et al., 2001) have been reported to express CD73. 
5.2 Functions  
It has been proposed that CD73 behaves as an adhesion molecule modulating lymphocyte-
endothelial cell interactions (Airas et al., 2000). Furthermore, CD73 is known to play a 
critical role in vivo in maintaining the integrity of the vascular endothelium during hypoxia 
(Colgan et al., 2006), in mediating efficient entry of lymphocytes into the central nervous 
system during experimental autoimmune encephalomyelitis and in regulating leukocyte-
endothelium interaction during cardiac ischemia–reperfusion (Koszalka et al., 2004).  
CD73 catalyzes the dephosphorylation of purine and pyrimidine ribo- and 
deoxyribonucleoside monophosphates to the corresponding nucleoside.  This ectoenzymatic 
cascade operates in tandem with CD39 (ecto-ATPase) and catalyzes the conversion of AMP 
to bioactive adenosine from adenosine triphosphate (ATP) which is often released into the 
extracellular environment from damaged or inflamed target cells (Stagg et al., 2010b). 
Extracellular adenosine induces potent immunosuppressive effects, mainly mediated 
through four adenosine-binding G protein–coupled receptors. In addition to its enzymatic 
function, CD73 has been suggested to have a role in T cell signalling (Resta et al., 1998). 
The resistance of many solid tumours to host immune responses has been largely attributed 
to a spectrum of tumour-associated immune-suppressive mechanisms. During tumour 
progression, tumour cells promote a tolerant microenvironment and activation of multiple 
immunosuppressive mechanisms, which may act in concert to attenuate an effective 
immune responses (Rabinovich et al., 2007). It is thought that tipping the balance from an 
immune-suppressive to an immune-active environment is necessary for effective cancer 
immunotherapy (Rabinovich et al., 2007). Adenosine is a purine nucleoside reaching high 
concentrations within solid tumours (Ohta et al., 2006) where it promotes tumour growth 
through the stimulation of tumour angiogenesis (Stagg & Smyth, 2010b) and inhibition of 
anti-tumour immune responses (Hoskin et al., 2008). However, the mechanisms whereby 
adenosine accumulates in solid tumours and the effects resulting from this accumulation are 
not completely understood.  
CD73 expression has been reported in several tumour types (Stagg & Smyth, 2010b), 
including ovarian cancer (Jin et al., 2010) and its expression has been associated with a 
prometastatic phenotype in melanoma and breast cancer (Leth-Larsen et al., 2009). Although 
in vitro studies suggested that CD73 expression can enhance breast cancer cell migration and 
invasion, the underlying mechanisms remain elusive. In breast cancer cells, CD73 
expression significantly inhibits endogenous adaptive anti-tumour immunosurveillance, in 
addition, CD73-derived adenosine enhances tumour cell migration in vitro and metastasis in 
vivo through the activation of A2B adenosine receptors (Stagg et al., 2010a). CD73 expression 
has been shown to be regulated by estrogen receptors, whereby loss of  estrogen receptors 
significantly enhances CD73 expression (Spychala et al., 2004). CD73 is highly expressed in 
many human solid tumours (Salmi et al., 2011), and its high expression and activity are 
associated with tumour invasiveness and metastasis (Stagg et al., 2010a) and with shorter 
patient survival. Recently it has been demonstrated that exosomes released by cancer cells in 
vitro and in biological effusions are able to dephosphorylate exogenous ATP and 5′AMP to 
form adenosine. These hydrolytic activities have been in part attributed to expression of 
functional CD39 and CD73 by exosomes. This mechanism may contribute to augmenting 
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adenosine levels within the tumour microenvironment and hence participate to the negative 
regulation of T cell function (Clayton et al., 2011). 
CD73 expressed in ovarian cancer negatively modulates tumour antigen-specific T cell 
immunity. Indeed, it has been demonstrated that knockdown of CD73 on tumour cells by 
siRNA improved anti-tumour T cell responses, completely restoring the efficacy of adoptive 
T cell therapy and leading to long-term tumour-free survival in tumour-bearing mice. 
Moreover, in a mouse model,  host CD73 deficiency decreased the ovarian carcinoma 
burden and increased mouse survival in a T cell–dependent manner. Accordingly, reduction 
of both tumour and host CD73 resulted in an optimal anti-tumour effect (Jin et al., 2010).  
Pharmacological blockade of CD73 using the specific inhibitor ǂ,ǃ-methylene adenosine 5′-
diphosphate (APCP) or a blocking anti-CD73 monoclonal antibody inhibited tumour 
growth and promoted efficacy of adoptive T cell therapy (Zhang, 2010), suggesting that 
CD73-targeted therapy might be a promising and rational approach to cancer treatment 
(Häusler SF et al., 2011). In summary, detailed analysis of CD73 expression on tumour cells 
and/or host cells regulating anti-tumour immunity may have important consequences on 
our understanding of immunosuppressive mechanisms in the tumour microenvironment 
that support tumour evasion. Inhibition of CD73 could be a therapeutic adjuvant to improve 
cancer immunotherapy. 
6. CD157 
6.1 Structure and expression 
CD157/BST-1 is a GPI-anchored glycoprotein encoded by a member of a gene family of 
NADase/ADP-ribosyl cyclase, which includes CD38.  The CD38 and bone marrow stromal 
cell antigen 1 (BST-1) genes arose by gene duplication before the divergence of humans and 
rodents (Ferrero et al., 1997). The human CD157 gene is located on chromosome 4p15, it 
spans ~35 kb and consists of nine exons (Muraoka et al., 1996). Although CD157 was 
initially characterised as a stromal (Kaisho et al., 1994) and myeloid surface antigen 
(Goldstein et al., 1993), it is also expressed by certain other cell types that include vascular 
endothelial cells (Ortolan et al., 2002) and mesothelial cells (Ross et al., 1998).  
6.2 Functions  
CD157 is an ectoenzyme that cleave extracellular nicotinamide adenine dinucleotide 
(NAD) and NADP+, generating cyclic ADP ribose (cADPR), NAADP+, and ADPR. Beside 
their role as mediators of intracellular calcium release (Galione, 1994), the products of 
CD157-operated NAD cleavage can act as extracellular immunomodifiers (Haag et al., 
2007). Emerging data indicated that these metabolites can act extracellularly as paracrine 
factors (Moreschi et al., 2008). Moreover, the catalytic reactions generate substrate for 
ADP-ribosyl transferases and polymerases involved in cell signalling, DNA repair and 
apoptosis (Haag et al., 2007). In addition, CD157 possesses receptor activity, indeed, it 
interacts with other surface molecules thus acquiring the ability to transduce signals 
(Malavasi et al., 2008). Accumulating evidence indicates that CD157 is a key molecule in 
the control of leukocyte adhesion, migration and diapedesis (Funaro, 2004; Ortolan, 2006). 
CD157 establishes a structural interaction with ǃ1 and ǃ2 integrins (Lavagno et al., 2007) 
and, following antibody-induced cross-linking, promotes their relocation into detergent-
resistant membrane domains, thus driving the dynamic reorganization of signalling-
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competent membrane microdomains. Moreover, CD157 effectively contributes to the 
integrin-driven signalling network that is critical during leukocyte transmigration (Lo 
Buono et al., 2011). 
Recently, we demonstrated that CD157 is expressed in epithelial ovarian cancer (EOC) 
primary cell cultures and tissues, and it is involved in interactions among EOC cells, 
extracellular matrix proteins, and mesothelial cells which ultimately control tumour cell 
migration and invasion. The results inferred in vitro were validated by clinical evidence: 
CD157 was expressed by 93% of EOC analysed and high CD157 expression was associated 
with rapid tumour relapse in patients. Moreover, CD157 appears to be a marker of poor 
prognosis in the serous subtype of ovarian cancer, which is the most frequent and 
aggressive type. Multivariate survival analysis showed that CD157 is an independent 
prognostic factor of tumour relapse shortly after surgical debulking of ovarian cancer 
(Ortolan et al., 2010). Several lines of evidence point to the fact that high levels of CD157 are 
associated with more aggressive ovarian cancer. First, forced expression of CD157 in CD157-
negative NIH:OVCAR-3 cells substantially increased cell motility, a prerequisite for 
dissemination. Second, blockade of CD157 activity, either by a specific monoclonal antibody 
in vitro or by its weak expression in patients, was associated with reduced invasion and 
migration by tumour cells. Finally, clinical observations revealed that high CD157 correlated 
with rapid tumour relapse (Ortolan et al., 2010). However,  how CD157 might contribute to 
a more aggressive ovarian cancer remains to be defined (Annunziata et al., 2010). Our 
results support the rationale for the future use of CD157 as a potential diagnostic target for 
EOC, providing the opportunity to develop new strategies using CD157 as a therapeutic 
target to prevent tumour dissemination in patients with serous ovarian cancer.  
7. Autotaxin/CD203c 
7.1 Structure and expression 
Autotaxin (ATX) also known as CD203c or ENPP2 (ectonucleotide 
pyrophosphatase/phosphodiesterase 2), is a cell motility–stimulating factor originally 
isolated from human melanoma cells (Stracke et al., 1992). It is a member of the ENPP 
protein family, which includes membrane-associated or secreted ectoenzymes that 
hydrolyze pyrophosphate or phosphodiester bonds in various extracellular compounds, 
such as nucleotides and lysophospholipids (Tokumura et al., 2002). ATX/CD203c is a 
soluble 125 kDa glycoprotein encoded by a single gene located on human chromosome 8. 
Three alternatively spliced isoforms have been reported: ǂ, ǃ and Ǆ. Isoform ǃ, considered 
the canonical form, is the predominant one, and is expressed in peripheral tissues while 
isoform Ǆ is more highly expressed in the central nervous system. Both ǃ and Ǆ variants are 
catalytically active, whereas the ǂ isoform is rapidly degraded into smaller inactive forms 
(Giganti et al., 2008). Autotaxin contains a catalytic domain, which is responsible for 
enzymatic activity and two additional domains, a somatomedin-B-like domain and a 
nuclease-like domain, which are located at the N-terminus and C-terminus of the protein, 
respectively. The somatomedin-B-like domain is rich in cysteine residues and contains an 
RGD tripeptide motif that is possibly involved in cell-extracellular matrix interactions. The 
nuclease-like domain contains an EF hand-like motif, structurally similar to the DNA- or 
RNA-non-specific endonucleases but it is catalytically inactive. All three domains are 
required for the catalytic activity (Nishimasu et al., 2011).  
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ATX is predominantly expressed in brain, kidney, placenta, ovary, small intestine and in 
body fluids such as plasma (Tokumura et al., 2002), cerebral spinal fluid, saliva, and 
follicular and amniotic fluids (Giganti et al., 2008; Nishimasu et al., 2011).   
7.2 Functions 
Autotaxin is defined as a multi-functional protein producing (i) lysophosphatidic acid (LPA) 
by conversion of lysophosphatidylcholine (LPC), present in human serum or plasma, and 
(ii) cyclic phosphatidic acid (cPA), an LPA analogue with distinct physiological activities. 
ATX activity accounts for the majority of LPA production in blood (Nakanaga et al., 2010). 
The biological activity of LPA is largely mediated through the activation of five receptors, 
LPA1 to LPA5. All of these are type I, rhodopsin-like G protein-coupled receptors with 
seven-transmembrane alpha helices (Lin et al., 2010). LPA evokes a wide variety of cellular 
responses in different cell types including Ras-mediated cell proliferation and Rho/Rac-
regulated cell migration (including vascular endothelial cells migration), neurite retraction, 
platelet aggregation, smooth muscle contraction, actin stress fibers formation and 
cytokine/chemokine secretion. LPA levels are increased during pathological conditions of 
the brain (neuropsychiatric disorders such as bipolar disorders, schizophrenia, etc.). 
Deregulation of LPA signalling is found in cardiovascular diseases: the formation of excess 
fibrous connective tissues is strongly influenced by receptor-mediated LPA signalling in 
different organs (for example, lung, kidney and liver) (Lin et al., 2010). Moreover, in both in 
vivo and in vitro systems, LPA has been shown to participate in critical events of cancer 
progression such as cell proliferation, growth, survival, migration, invasion, and promotion 
of angiogenesis (van Meeteren et al., 2007). Therefore, LPA signalling is worth considering 
for its involvement in disease processes as well as in normal physiological functions.  
Autotaxin was originally identified as a tumour cell motility factor released in the spent 
medium of human melanoma cells. When overexpressed in Ras-NIH3T3 cells, ATX 
promotes tumour aggressiveness, metastasis and angiogenesis in nude mice (Nam et al., 
2000). ATX is highly expressed in several human cancers, including glioblastoma, lung and 
breast cancer, renal cell carcinoma, neuroblastoma, thyroid carcinoma and Hodgkin’s 
lymphoma (Mills et al., 2003). High ATX expression is detected in glioblastoma multiforme, 
a lethal cancer with a high infiltration rate (Hoelzinger et al., 2005). ATX has also been found 
upregulated in stromal cells from prostate carcinoma patients (Zhao et al., 2007) and its 
expression is strongly enhanced by v-Jun oncogene-induced transformation (Black et al., 
2004) and by overexpression of cancer-associated ǂ6ǃ4 integrin in breast cancer (Chen et al., 
2005). In an in vivo angiogenesis model, ATX-transfected Ras-transformed NIH3T3 cells 
caused more prominent new blood vessel formation than control cells (Nam et al., 2000). In 
addition, ATX stimulates human vascular endothelial cells grown on Matrigel to form 
tubules, similarly to the effects induced by vascular endothelial growth factor (VEGF) (Nam 
et al., 2001).  
Recent studies have demonstrated the molecular mechanisms underlying the ATX/LPA 
axis in cancer. ATX-induced motility of melanoma cells is mediated through the activation 
of focal adhesion kinase (FAK) (Jung et al., 2004) and, in the nucleus, by the DNA binding of 
necrosis factor kappa B (NF-kB) (Lee et al., 2006). 
Another finding is that LPA strongly counteracts Taxol-induced death in the MCF-7 breast 
cancer cell line and in MDA-MB-435 melanoma cells, by activating phosphatidylinositol 3-
kinase (PI3K), which antagonizes the Taxol-induced accumulation of cancer cells in the 
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G2/M phase of the cell cycle (Samadi et al., 2009). Recently it has been demonstrated that 
the ATX/LPA axis allows breast cancer cells to escape from mitotic arrest following the 
PI3K-dependent displacement of Taxol from polymerised tubulin (Samadi et al., 2011). 
Moreover, recent data from in vivo experiments indicate that increased expression of ATX, 
LPA1, LPA2 or LPA3 receptors in mice is associated with enhanced invasiveness of estrogen 
receptor-positive, metastatic breast cancers (Liu et al., 2009). Finally, the significance of the 
plasma or serum ATX levels in cancer patients has been reported in patients with follicular 
lymphoma, where serum ATX levels proved to be significantly higher than those in healthy 
subjects, to correlate with plasma LPA levels and to change according to patient clinical course 
(Masuda et al., 2008). Additional studies have reported an impressive and specific increase 
in serum ATX activity and plasma LPA in patients with chronic hepatitis C (Watanabe et al., 
2007) and pancreatic cancer (Nakai et al., 2011). 
In the last 20 years several studies have considered the potential role of the ATX/LPA axis 
in ovarian cancer. The high metastatic potential of ovarian carcinoma was suggested to be 
related to increased local production of LPA in the peritoneal cavity (Mills & Moolenaar, 
2003). Levels of LPA are markedly elevated in the ascites of patients with EOC (Mills et al., 
1988) and in the plasma of 90% of stage I ovarian cancer patients, compared with healthy 
women (Xu et al., 1998). 
The outcomes of LPA-driven signalling are determined by the expression level of LPA 
receptors on the cell surfaces. Indeed, normal ovarian epithelial cells express low levels of 
mRNA for LPA2 and LPA3, whereas the mRNA levels for LPA2 and particularly LPA3, are 
elevated in EOC (Fang et al., 2002), suggesting a shift on ovarian cancer cells towards an 
LPA-dependent phenotype. Moreover >90% of LPA degradation by ovarian cancer cells is 
caused by the action of lipid phosphate phosphohydrolase-like (LPP-like) enzymes, whose 
expression differs between normal ovarian epithelium and epithelial ovarian cancer (Imai et 
al., 2000). This implies that LPA, its receptors and downstream metabolic cascade might be 
potential targets for the design of novel ovarian cancer therapies.  
LPA has been found to induce VEGF expression (Hu et al., 2001) which in turn contributes 
to malignant ascites formation by increasing peritoneal microvessel permeability (Nagy et 
al., 1995). A feedback model between ATX, LPA and VEGF in ovarian cancer cells has been 
recently proposed (Ptaszynska et al., 2008). VEGF activates ATX transcription and 
subsequent protein secretion through VEGFR2. Increased secretion of ATX leads to an 
increased level of extracellular LPA. Completing the loop, LPA can stimulate VEGF and 
VEGFR2 expression through LPA receptor signalling thus enhancing tumour survival and 
growth. These data indicate that cross-talk between ATX and VEGF may be an important 
autocrine mechanism in the generation of an aggressive ovarian cancer phenotype. In 
addition, soluble ATX may be a beneficial target for cancer therapy because of its capacity to 
control both LPA production and signalling, and VEGF signalling. 
The development of drug resistance to cytotoxic therapies such as carboplatin and paclitaxel as 
well as to newly emerging therapies (Agarwal et al., 2003), remains a high risk factor for 
ovarian cancer patients. Therefore, the identification of genes which confer drug resistance 
may offer novel therapeutic targets that can be exploited to develop drugs which re-sensitize 
tumour cells to chemotherapeutic agents (Richardson et al., 2005). ATX has been linked to 
chemoresistance due to its ability to inhibit apoptosis induced by paclitaxel in breast cancer 
cells (Samadi et al., 2009) and LPA can inhibit cell death induced by cisplatin (Frankel et al., 
1996). It has been demonstrated that ATX may be a target for treating drug-resistant ovarian 
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cancer. The ectopic expression of ATX leads to the activation of a PI3K/Akt-mediated survival 
pathway, suggesting that ATX can delay carboplatin-induced cell death through the 
generation of LPA and the subsequent activation of the PI3K/Akt pathway (Vidot et al., 2010).  
The inhibition of ATX in therapy has the advantage of providing a single extracellular drug 
target capable of blocking production of LPA. It has been observed that the primary effect of 
ATX is to delay apoptosis induced by carboplatin; since the exposure of tumour cells to 
carboplatin in patients is transient, accelerating the induction of apoptosis might be beneficial 
and may lead to improved tumour cell destruction.  
 
 
Fig. 2. Schematic representation of the role of ectoenzymes in the main steps of ovarian 
cancer progression. Ectoenzymes in red have stimulating effects, those in green have 
inhibitory effects on the indicated steps. 
8. Conclusion 
Improved understanding of the underlying biology of ovarian tumour progression and 
chemoresistance has led to the development of molecular targeted therapies. Ectoenzymes 
are attractive targets for designing new strategies to interfere with ovarian cancer 
progression and recurrence. This can be achieved by inhibiting the ectoenzymes that 
promote tumour migration and invasiveness (such as CD157 and CD13) or by inducing the 
activity of ectoenzymes that normally counteract tumour progression (such as CD26). In 
many cases, ectoenzymes can be inactivated either by specific monoclonal antibodies that 
block their function, or by small-molecule enzyme inhibitors. The dual nature of 
ectoenzymes warrants more detailed and vigorous investigation, because some of their 
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functions seem to be independent of their enzymatic activities. It is conceivable that the 
large extracellular domains of ectoenzymes and their lateral interaction with other 
membrane proteins can mediate responses without involvement of their catalytic activity. 
However, many of the non-substrate ligands of ectoenzymes remain to be identified. 
Moreover, increasing evidence indicates that a number of ectoenzymes orchestrate the 
immune mechanisms underlying tumour progression and outcome and it is now evident 
that ovarian cancer features a number of different tumour evasion mechanisms. The future 
challenge will be to use a combinatorial approach to increase the existing anti-tumour 
response, dampen tumour evasion mechanisms and target crucial environmental players. 
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